Recursion Pharmaceuticals, Inc. beat EPS estimates 67% of the time across 3 reported quarters (2 beats, 1 misses). Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result |
|---|---|---|---|---|
| Q22026 FY2026 | $-0.23 | $-0.25 | -8.7% | Miss |
| Q12026 FY2026 | $-0.30 | $-0.22 | +26.7% | Beat |
| Q42025 FY2025 | $-0.28 | $-0.21 | +25.0% | Beat |
Back to RXRX overview · RXRX holders · RXRX KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.